Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Shea who wrote (10129)	7/28/1999 10:32:00 AM
From: Rande Is	Read Replies (1) \| Respond to of 57584

Speaking of healthcare stocks, Kevin. . . how about sticking MYL on your watch list. It hit an off quarter, but has been making a slow recovery after being spanked with lawsuits from the major drug makers and FTC investigations for not playing fair. . . .result was that the bureau that oversees the FTC bit their head off for preferring the major drug makers and making MYL the target of their investigation, though it was inconsistent with previous investigations performed by that agency. Sent both the FTC and the major drug makers yiping home with their tails between their legs. Today MYL is getting a butch haircut for showing a bad quarter. . . but I'd imagine most of their bucks went to legal fees. . .just look at the news for the past 3 months. . . probably 7/8ths of it is legal. Why did this happen? MYL has many FDA approvals for making generic versions of the most popular drugs. And the sales they have taken away from the majors has not gone unnoticed. MYL did corner the market on a particular drug and overcharged. . . for some reason, it is OK for the majors to do that. . . a common practice, but if a generic company does same, then they all cry foul. . .and sick their FTC buddies on them. Anyway, MYL signed some new Canadian distribution deals and has been given even more green lights recently. If this one will break below 22, where it opened, it could fall under 20. . .making it a nice undervalued mid-cap long-term play. . .as well as a possible swing play on the bounce. Trading has been between 22 and 23 all day. It is OK from 22, but better under, IMO. . . I like the generics like Mylan and [BRL] Barr Labs. . . as the price of drugs rises and the fear of "generics" subsides. . .I think they make a nice companion to the majors in a portfolio. . .like holding Federated Dept stores, but also Family Dollar and Wal-Mart. . . . .also FDA has been awarding approval generously. And the lead time is only about 3 years as I recall. . . Rande Is